search
Back to results

Lavender Aromatherapy on Sleep Quality and Metabolic Parameters of Type 2 Diabetic Patients With Insomnia (LavenAromDM)

Primary Purpose

Diabetes Mellitus, Type 2, Sleep Disturbance

Status
Completed
Phase
Not Applicable
Locations
Iran, Islamic Republic of
Study Type
Interventional
Intervention
Lavender Oil
Placebos
Sponsored by
Shiraz University of Medical Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

25 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diabetes mellitus type 2
  • Age between 25-65 years old
  • Fasting Blood Sugar between 70-130
  • 2 hour post prandial glucose less than 180.
  • HbA1C less than 7
  • Sleep disorder according to pittsburgh Insomnia Rating Scale more than 5.

Exclusion Criteria:

  • Any systemic illnesses
  • Use of sedative or antidepressant drugs
  • Pregnancy
  • Lactation
  • History of allergic reaction to Lavender
  • History of allergic rhinitis, asthma and respiratory disorders
  • Anosmia
  • Headache that start with smell
  • Cigarette smocking or substance abuse
  • Hospitalization or surgery within 1 months ago.
  • Work shift

Sites / Locations

  • Shahid Motahhari Clinic, Shiraz University of Medical Sciences
  • Shiraz University of Medical Sciences

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Lavender oil

vehicle (Almond oil)

Arm Description

Outcomes

Primary Outcome Measures

Pittsburgh Insomnia Rating Scale
evaluate the sleep disorder with Pittsburgh Insomnia Rating Scale

Secondary Outcome Measures

Fasting Blood Sugar
blood sample
2 hours Post Prandial Glucose
blood sample
Serum Insulin
blood sample
C Reactive Protein
blood sample
Uric acid
blood sample
Creatinine
blood sample
Triglyceride
blood sample
Cholesterol
blood sample
Low Density Lipoprotein
blood sample
High Density Lipoprotein
blood sample
Aspartate Aminotransferase
blood sample
Alanine Aminotransferase
blood sample
weight
Scale
Body Mass Index
Body Mass Index
waist circumference
Meter
hip circumference
Meter
Systolic Blood Pressure
Blood Pressure measurement by digital sphygmometer
Diastolic Blood Pressure
Blood Pressure measurement by digital sphygmometer

Full Information

First Posted
July 25, 2017
Last Updated
April 4, 2019
Sponsor
Shiraz University of Medical Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT03304938
Brief Title
Lavender Aromatherapy on Sleep Quality and Metabolic Parameters of Type 2 Diabetic Patients With Insomnia
Acronym
LavenAromDM
Official Title
Efficacy and Safety of Lavender Aromatherapy on Sleep Quality and Metabolic Parameters of Type 2 Diabetic Patients With Insomnia
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
February 1, 2018 (Actual)
Primary Completion Date
November 1, 2018 (Actual)
Study Completion Date
December 1, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shiraz University of Medical Sciences

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is designed as cross-over double-blind placebo-controlled randomized clinical trial that 40 diabetic patients with sleep disorder with the inclusion criteria will enter into the study and randomly assign to first intervention and first placebo groups.The primary outcomes are change in sleep disorder and metabolic parameters that will be evaluated at the end of the study.
Detailed Description
Considering the high prevalence of sleep disturbance in diabetic patients and the effectiveness of lavender in treatment of sleep disorders in this study the efficacy of Lavender aromatherapy in sleep disorder and metabolic parameters in diabetic patients will be investigated. This study is designed as cross-over double-blind placebo-controlled randomized clinical trial that 40 diabetic patients with sleep disorder with the inclusion criteria will enter into the study and randomly assign to first intervention and first placebo groups.The primary outcomes are change in sleep disorder and metabolic parameters that will be evaluated at the end of the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2, Sleep Disturbance

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
40 diabetic patients with sleep disorder with the inclusion criteria will enter into the crossover study and randomly assign to treatment or placebo groups.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Lavender Essential oil as medication and almond oil as placebo put in similar dark buttle and the head of placebo bottle aromatized whit Lavender Essential oil and all of participants, care provider, investigator and outcomes assessor will be blind.
Allocation
Randomized
Enrollment
36 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lavender oil
Arm Type
Active Comparator
Arm Title
vehicle (Almond oil)
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Lavender Oil
Intervention Description
The intervention group pour 3 drops of Lavender essential oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
Intervention Type
Drug
Intervention Name(s)
Placebos
Intervention Description
The placebo group pour 3 drops of Almond oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
Primary Outcome Measure Information:
Title
Pittsburgh Insomnia Rating Scale
Description
evaluate the sleep disorder with Pittsburgh Insomnia Rating Scale
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Fasting Blood Sugar
Description
blood sample
Time Frame
4 week
Title
2 hours Post Prandial Glucose
Description
blood sample
Time Frame
4 week
Title
Serum Insulin
Description
blood sample
Time Frame
4 week
Title
C Reactive Protein
Description
blood sample
Time Frame
4 week
Title
Uric acid
Description
blood sample
Time Frame
4 week
Title
Creatinine
Description
blood sample
Time Frame
4 week
Title
Triglyceride
Description
blood sample
Time Frame
4 week
Title
Cholesterol
Description
blood sample
Time Frame
4 week
Title
Low Density Lipoprotein
Description
blood sample
Time Frame
4 week
Title
High Density Lipoprotein
Description
blood sample
Time Frame
4 week
Title
Aspartate Aminotransferase
Description
blood sample
Time Frame
4 week
Title
Alanine Aminotransferase
Description
blood sample
Time Frame
4 week
Title
weight
Description
Scale
Time Frame
4 week
Title
Body Mass Index
Description
Body Mass Index
Time Frame
4 week
Title
waist circumference
Description
Meter
Time Frame
4 week
Title
hip circumference
Description
Meter
Time Frame
4 week
Title
Systolic Blood Pressure
Description
Blood Pressure measurement by digital sphygmometer
Time Frame
4 week
Title
Diastolic Blood Pressure
Description
Blood Pressure measurement by digital sphygmometer
Time Frame
4 week

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diabetes mellitus type 2 Age between 25-65 years old Fasting Blood Sugar between 70-130 2 hour post prandial glucose less than 180. HbA1C less than 7 Sleep disorder according to pittsburgh Insomnia Rating Scale more than 5. Exclusion Criteria: Any systemic illnesses Use of sedative or antidepressant drugs Pregnancy Lactation History of allergic reaction to Lavender History of allergic rhinitis, asthma and respiratory disorders Anosmia Headache that start with smell Cigarette smocking or substance abuse Hospitalization or surgery within 1 months ago. Work shift
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mesbah Shams, M.D.
Organizational Affiliation
Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences
Official's Role
Study Chair
Facility Information:
Facility Name
Shahid Motahhari Clinic, Shiraz University of Medical Sciences
City
Shiraz
State/Province
Fars
Country
Iran, Islamic Republic of
Facility Name
Shiraz University of Medical Sciences
City
Shiraz
State/Province
Fars
Country
Iran, Islamic Republic of

12. IPD Sharing Statement

Learn more about this trial

Lavender Aromatherapy on Sleep Quality and Metabolic Parameters of Type 2 Diabetic Patients With Insomnia

We'll reach out to this number within 24 hrs